Skip to main content
OpenTrials
Completed

NCT Number: NCT07074808

RCT aiTriage Chest Pain Risk Stratification

Chest pain is one of the most common reasons people visit the Emergency Department (ED). While most cases are not serious, a small number may lead to life-threatening heart problems, known as Major Adverse Cardiac Events (MACE). Emergency staff need to quickly identify these high-risk patients, but current methods often take time, involve lab tests, and strain already busy EDs.

In Singapore, for example, SGH sees over 120,000 ED patients a year. In the U.S., chest pain accounts for around 8-10 million ED visits annually, yet fewer than 10% are ultimately diagnosed with MACE. Still, over half of chest pain patients undergo extensive and costly testing, adding up to $10-13 billion each year. This over-testing is done to avoid missing a critical case, but it's inefficient and stressful for both staff and patients.

Traditional risk scoring tools like TIMI, GRACE, HEART, and EDACS require time and blood test results, delaying early intervention. Waiting times in EDs can be 1-2 hours, during which patient conditions may worsen unnoticed.

To address this, we've developed aiTriage, a portable device that uses AI to analyze heart rate variability, ECG readings, blood pressure, and oxygen levels. It provides a real-time risk score within 5 minutes, helping doctors decide which patients need urgent care. Unlike current methods, aiTriage works without waiting for lab tests and can ease the load on EDs.

No existing devices offer real-time MACE risk scoring like aiTriage. Our previous studies show that this system outperforms standard tools and could transform how chest pain is managed in emergency care, saving time, money, and lives.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Chest Pain Disease Attributes Emergencies Neurologic Manifestations Pain Pathologic Processes Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

21 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

National University Hospital, Singapore

Loading trial locations.

About this study

Primary Aim

  • To compare the admission rate defined as number of patients admitted/ all patients presenting to ED with chest pain (Inpatient admission or Emergency Observation Ward admission) of HRV guided accelerated diagnostic protocol (HRV-ADP) to the current standard protocol.
  • To evaluate the implementation of HRV-ADP and understand the potential factors affecting implementation success in routine practice using the REAIM/PRISM framework

Secondary Aim

  • To determine 30-day MACE between groups for discharged patients.
  • To determine ED length of stay from registration to admission decision between groups.
  • To calculate predicted aiTriage HRV-ADP admission rate vs actual (control group).

Primary Hypothesis - There will be a 10-20% reduction in admission rate with HRV-ADP comparing to the Standard protocol currently in practice.

Secondary Hypothesis

  • There is no increase in Major Adverse Cardiac Events (MACE) between groups for discharged patients.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • All ED patients (≥21 years old) with chest pain suspected of having ACS will be eligible for being included in this study.

Exclusion criteria

  • Patients who are not in sinus rhythm
  • Patients who do not have mental capacity.
  • Patients with unstable vital signs, STEMI, obvious ACS, and non cardiac cases like rib fractures, pneumothorax.
  • Patients lost to follow- up or transferred to other hospitals within the 30 day time frame.
  • Patients with a high percentage of artefacts and ectopics exceeding 30% of ECG recordings will be excluded.

Treatment and study plan

aiTriage risk score

Device

Risk score generated by AI App aiTriage for chest pain patients

Primary outcomes

  1. Admission rate

    Time frame: Throughout in ED, an average of 3 days

    [number of patients admitted] divided by [all patients presenting to ED with chest pain]

Secondary outcomes

  1. 30-day MACE

    Time frame: 30 days starting from admission to ED

    Any major adverse cardiac events occurred in ED/hospital till discharged/death

  2. Hospital Length of Stay

    Time frame: Within hospital stay, an average of 7 days

    From ED registration date/time to ward admission decision between groups

  3. HRV-ADP Admission Rate

    Time frame: within hospital stay, an average of 7 days

    Admission rate (Intervention group vs Control Group)

Sponsors and collaborators

Lead sponsor

Singapore General Hospital

Other

Registry information

Official study title

HRV Guided Accelerated Diagnostic Protocol for Chest Pain Patients - Randomised Control Trial (HRV-ADP RCT)

Important dates

Study start
2022
Primary completion
2025
Study completion
2025
First posted
Jul 20, 2025
Registry last updated
Jan 8, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.